ClinicalTrials.gg
Status unknownNCT03840928Updated Dec 13, 2023

PatientSpot Formerly Known as ArthritisPower

An observational study in Rheumatoid Arthritis, Ankylosing Spondylitis and Fibromyalgia, sponsored by Global Healthy Living Foundation. Status unknown at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Global Healthy Living Foundation · Observational

The sponsor has not verified this record recently (last verified Dec 2023), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40,000
Ages
19 Years and older
Sex
All
01

Study summary

Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psoriasis, and other chronic inflammatory or immune-mediated conditions. In addition, since patients with chronic conditions often have other co-morbidities like cardiovascular health and obesity-related metabolic disorders, these conditions will also be included. Participants will provide information from their smartphones or personal computers. The information will be used by researchers and clinicians to help patients and their providers make better, more informed decisions about treatment of chronic conditions.

Read the detailed description

Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with rheumatoid arthritis (RA), spondyloarthritis (SpA), other musculoskeletal conditions, chronic neurological conditions like migraine, chronic pulmonary conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, autoimmune dermatological conditions such as psoriasis, and other chronic inflammatory or immune-mediated conditions. In addition, since patients with chronic conditions often have other co-morbidities like cardiovascular health and obesity-related metabolic disorders, these conditions will also be included. Participants will provide information from their smartphones or personal computers. The information will be used by researchers and clinicians to help patients and their providers make better, more informed decisions about treatment of chronic conditions.

We have established a governance structure with highly engaged patients and stakeholders who will serve on a Patient Governor Group (PGG) and Research Advisory Board (RAB) to ensure Patient Power participant privacy and transparency about research activities. Online tools and a mobile application at me securely capture patient data. The software tools built include real-time connection to the adaptive version of NIH Patient Reported Outcomes Measurement Information System (PROMIS) instruments capturing patient reported data that minimizes participant burden and allows participants to immediately view their scores if they choose. The Patient Power App runs on both web browsers and smartphones with data stored in the Amazon Web Services (AWS) cloud, not on a participant's smartphone or browser. The App has four key design pillars: (1) Patient engagement, community integration and education by incorporating GHLF bloggers and chronic disease news and social media engagement to the app for education, support and research findings to be shared directly and immediately with those living with registry-eligible chronic conditions; (2) Personal longitudinal health and medication tracking by providing participants' access to their actively contributed patient reported outcome (PRO) and other health-related data (e.g. current and past medications). We will use messaging to encourage participants to regularly update their information, including medication information. For example, we may remind participants to contribute their medication information with the following message: "You don't have any active medications. You can record your medications in Patient Power. By adding your active medications, you will be able to see how your symptoms have changed since starting a new medication. Click here to start entering medications". (3) Health care decision making by allowing App users to share health tracking reports at their discretion with their providers or caregivers; and (4) Research opportunities by providing a platform where an array of new research opportunities can be browsed by participants to combat chronic diseases. The combination of solid governance structure with well-developed policies and procedures, engaged patient community, collaborative relationships with many research partners and our innovatively convenient and mobile approach to data collection make Patient Power a unique and powerful patient-led initiative in chronic disease research.

02

Conditions studied

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Fibromyalgia
  • Gout
  • Crohn Disease
  • Juvenile Idiopathic Arthritis
  • Lupus Erythematosus
  • Myositis
  • Osteoarthritis
  • Osteoporosis
  • Psoriasis
  • Psoriatic Arthritis
  • Scleroderma
  • Dermatomyositis
  • Inflammatory Bowel Diseases
  • Polymyositis
  • Axial Spondyloarthritis
  • Diffuse Idiopathic Skeletal Hyperostosis
  • Polymyalgia Rheumatica
  • Giant Cell Arteritis
  • Temporal Arteritis
  • Wegener
  • Relapsing Polychondritis
  • Undifferentiated Connective Tissue Disease
  • Spinal Cord Injuries
  • Alzheimer Disease
  • Amyotrophic Lateral Sclerosis
  • Ataxia
  • Bell Palsy
  • Brain Tumor
  • Cerebral Aneurysm
  • Epilepsy
  • Guillain-Barre Syndrome
  • Headache
  • Head Injury
  • Hydrocephalus
  • Lumbar Disc Disease
  • Meningitis
  • Multiple Sclerosis
  • Muscular Dystrophy
  • Neurocutaneous Syndromes
  • Parkinson Disease
  • Stroke
  • Cluster Headache
  • Tension-Type Headache
  • Chronic Obstructive Pulmonary Disease
  • Asthma
  • Lung Cancer
  • Cystic Fibrosis
  • Sleep Apnea
  • Eczema
  • Alopecia
  • Chronic Inflammation
  • Unstable Angina
  • Heart Attack
  • Heart Failure
  • Arrythmia
  • Valve Heart Disease
  • High Blood Pressure
  • Congenital Heart Disease
  • Peripheral Arterial Disease
  • Diabetes
  • Chronic Liver Disease
  • Obesity
03

In context

Arthritis, Rheumatoid

2,962 studies on the registry are indexed under Arthritis, Rheumatoid; 396 are open to participants now.

This study's planned enrollment of 40,000 is above the median of 176 across 854 observational studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Global Healthy Living Foundation is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants will be derived from the population of people who indicate that they have been diagnosed by a physician with a chronic condition. al conditions will be invited to join the ArthritisPower research registry and download the PatientSpot App.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Self-report that a physician has given a diagnosis of a chronic condition listed in the registry.
  • The Registry is only intended at this time for residents of the United States and United States territories and Canada who are nineteen (19) years or older (for Puerto Rico residents, you must be 21 years or older to participate).

Exclusion criteria

Exclusion Criteria

  • Under 19 years old
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Ankylosing Spondylitis
  • Fibromyalgia
  • Gout
  • Crohn's-related Arthritis
  • Juvenile Idiopathic Arthritis
  • Lupus
  • Myositis
  • Osteoarthritis
  • Osteoporosis
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Scleroderma
06

What researchers measure

Primary outcomes

  1. Pain Interference (PROMIS)

    Time frame: 7 days

  2. Fatigue (PROMIS)

    Time frame: 7 days

  3. Sleep Disturbance (PROMIS)

    Time frame: 7 days

  4. Physical Function (PROMIS)

    Time frame: 7 days

  5. RAPID-3 (MD-HAQ with visual analogue scale for pain and patient global measure for overall health)

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
  • Global Healthy Living Foundation
    Upper Nyack, New York 10960, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2015 (actual). Primary completion is estimated for Mar 2025, 119 months after the start.

Of 196 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 96. This study's planned 119 months is above that.

Counting every sponsor, half of 317 studies reached it within 47 months; a quarter within 24 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2019
First posted
Feb 15, 2019
StartActual
Apr 1, 2015
Primary completionEst.
Mar 1, 2025
CompletionEst.
Mar 1, 2025
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03840928
Lead sponsor
Global Healthy Living Foundation
Responsible party
Shilpa Venkatachalam (Director, Patient-Centered Research Operations and Ethical Oversight, Global Healthy Living Foundation) — Principal investigator
First posted
Feb 15, 2019
Start date
Apr 1, 2015
Primary completion
Mar 1, 2025 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Dec 13, 2023

Study contacts

Shilpa Venkatachalam, PhD
Contact
bnowell@ghlf.org
(845) 348 0400 ext. 110
Laura Stradford, MPH
Contact
lstradford@ghlf.org
(845) 348 0400 ext. 210
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion